Starting date : Oct. 2017 > Sep. 2018
Lifetime: 24 months
Program in support : H2020-EU.1.2.1. - FET Open
Status project : complete
CEA-Leti's contact :
Remco den Dulk
Project Coordinator: Leiden University Medical Center (NL)
Partners: - BE: IMEC
- DE: Fraunhofer
- ES: Zaragosa University
- FR: CEA-Leti
- NL: Delft University, Human Organ and Disease Model Technologies, Leids Universitair Medisch Centrum
Target market: n/a
Publications:
Investment: € 0.5 m.
EC Contribution: € 0.5 m.
| Stakes
CEA-Leti has taken part in a bibliometric study, market analysis, expert interviews and panel discussions to survey the current landscape in research, development, applications and market opportunities for Organ-on-Chip (OoC) devices in order to build the foundations of a European OoC ecosystem. The report on these actions outlines the existing unmet needs, key challenges, barriers and perspectives in the field. It proposes recommendations for designing a European roadmap that could transform OoC systems (OoCs) into realistic models of human (patho)physiology in the near future.
Synergy-based convergence of microfabrication technologies and tissue engineering makes OoCs promising tools for realistic modeling of human physiology and pathology. The aim of an OoC is not to replicate a whole living organ but to sustain a minimum functional (sub) unit of an organ or tissue that can controllably recapitulate the salient aspects of human physiology.
For this purpose, the main and desired features of an OoC can be divided into three categories: Tissue architecture: • Integrated long-term cell culture in defined spatial organizations • Tissue-tissue interfaces/cell-cell contacts/cellular heterogeneity • Miniaturization.
Conditions: • Controlled microenvironment (topology, biochemistry, physics) • Controlled dynamics (fluid flow, electro-mechanical stimuli) • Continuous automated perfusion • Real-time monitoring of multiple physical, bio- and electro-chemical parameters • Automated reproducible multi-sample analysis, comparable or compatible with R&D robotics • Large-scale manufacturability.
Functions: • Physio- and pathological relevance • Recapitulation of organ structure and function • Recapitulation of dynamic mechanical biological properties and stimuli response of organs.
Organ-on-chip technology will revolutionize the healthcare domain by offering new, ground breaking solutions to different industries, especially in regenerative medicine and medication. ORCHID have achieved this through its 5 objectives: • Evaluate existing technology (state of the art and unmet needs) • Identify ethical issues, establish standards and identify measures for regulatory implementation • Analyze economic and social impact, training and education • Develop a roadmap for guiding required R&D efforts • Raise awareness and build an ecosystem for organ-on-chip technology using a digital reference platform (Creation of the European Organ-on-Chip Society EUROoCS).
IMPACT
ORCHID will have a broad impact: it will facilitate drug development, contribute significantly to reducing animal experiments and help in developing personalized medicine. The project will achieve these goals by providing a framework for principal stakeholders, bringing together key players and raising awareness of organ-on-chip technology throughout Europe.
|
|